Recent News for SCYX - SCYNEXIS, Inc.

Date Title
Jun 4 SCYNEXIS Inc (SCYX): Are Hedge Funds Right About This Stock?
Jun 2 SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales
Jun 1 3 “Strong Buy” Biotech Stocks Under $5 With Major Catalysts Approaching
May 11 SCYNEXIS EPS beats by $0.08
May 11 SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update
May 6 SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp
May 2 Stocks To Watch: Jobs Report, Virtual Conferences And Blue Chips On Tap
May 2 SCYNEXIS files for 19.4M common shares
Apr 28 SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
Apr 27 How Does SCYNEXIS, Inc. (NASDAQ:SCYX) Affect Your Portfolio Volatility?
Apr 21 Scynexis up 20% premarket on second positive study of ibrexafungerp
Apr 21 SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
Apr 13 Scynexis closes $20M stock purchase deal
Apr 13 SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement
Apr 12 The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates
Apr 9 Scynexis shores up finances with $10M convertible debt deal
Apr 9 SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital
Mar 26 SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020
Mar 19 The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Mar 13 Earnings Update: SCYNEXIS, Inc. Just Reported And Analysts Are Boosting Their Estimates
Mar 11 SCYNEXIS EPS misses by $0.10, misses on revenue
Mar 11 SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update
Mar 5 SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference
Feb 13 Scynexis completes enrollment in second pivotal study of ibrexafungerp
Feb 13 SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

Back to the Main SCYX Page...